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ABSTRACT

COMPARISON OF AN IN SITU DNA PROBE HYBRIDIZATION ASSAY AND
A RAPID ENZYME IMMUNOASSAY WITH CELL CULTURE FOR THE
DETECTION OF HERPES SIMPLEX VIRUS INFECTIONS

Denault, Jacquelyn S.
University of Dayton, 1994
Advisor: Dr. Robert Kearns

Rapid diagnosis of HSV is needed for better management of patients with HSV
infections. HSV isolation by cell culture remains the standard method for
diagnosis, despite the drawbacks associated with this test. The performance of an

in situ DNA probe hybridization assay (HSVDISK) and a rapid enzyme
immunoassay (Surecell) was evaluated in comparison to cell culture, which was

considered to be 100% accurate in the detection of HSV in clinical specimens. Of
154 specimens from both asymptomatic and symptomatic patients, 42 were tested

by Surecell and cell culture, and 152 were tested by HSVDISK and cell culture.
Based on cell culture results, incidence of herpetic infection in the patient

population was 23/154 (14.9%).

The sensitivity and specificity of the Surecell

assay were 88.9% and 87.9%, and those of the HSVDISK assay were 90.9% and

99.2%, respectively. The Surecell assay was an easy test to perform and was an
excellent screening test for positives, especially since virus present in the patient
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specimen did not need to be active for detection. However, the Surecell assay did
produce results that were difficult to read with respect to intensity of color for
5/42 specimens. The HSVDISK assay required minimal prior experience with cell

culture and was more compact and easier to work with than cell culture tubes.
However, this assay may not detect HSV in specimens with low titer. For rapid

diagnosis of an HSV infection, the 15 minute Surecell and 24 hour HSVDISK
assays are an improvement on cell culture, but cell culture can detect HSV in

specimens with low HSV titer, making it a more accurate detection method for
HSV infection.
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INTRODUCTION

Herpes simplex virus (HSV) infections are among the most common viral

infections affecting humans world wide. These infections are caused by two

genetically distinct viruses belonging to the alphavirinae subfamily of herpes
viruses, herpes simplex virus type-1 (HSV-1) and herpes simplex virus type-2
(HSV-2).

The anatomic site of HSV infection and the age and immune status of the

host determine the duration, severity, and type of HSV infection caused (1).
HSVs are capable of infecting most areas of the body (2, 3), however, in
immunocompetent hosts these infections are most commonly localized to skin,

mouth, pharynx, eyes, genitalia and brain. For immunosuppressed hosts HSV

infection can result in extensive damage to dermal tissue and could even result in

infection of visceral organs. The number of severe cases of HSV infection has
increased during recent years due to the widespread use of immunosuppressive

therapy in cancer and transplant patients and due to the increased number of
persons with AIDS (4).

In order for a primary infection to be established, HSV must overcome

host physical and chemical barriers (e.g intact skin and skin pH) as well as
nonspecific defense mechanisms (e.g. phagocytic and natural killer (NK) cell
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activity). HSV infection may not, however, always lead to productive replication

of virus and appearance of vesicular lesions. In fact the primary infection with
HSV typically results in symptoms that are so mild that the individual only

experiences a little discomfort (1, 5). In persons with genital HSV-2 infection,

asymptomatic primary episodes occur because childhood exposure to HSV-1 has

instituted partial immunity to HSV-2 (2, 5). Despite whether or not clinically
apparent lesions occur during a primary episode, neural tissue underlying the
original infection site usually becomes infected, resulting in establishment of latent

HSV which may later be reactivated from this neural tissue to cause recurrent
infection (2).

Acquired immunity has a role in limiting the severity of the HSV infection
but cannot prevent establishment of latent HSV and thus cannot prevent future
symptomatic recurrences of infection (6). Progeny HSVs are able to avoid

destruction by humoral immune mechanisms by spreading directly from cell to cell
by fusion of cell membranes, i.e., formation of syncytia (7). In this manner, HSVs

may never contact the extracellular environment, where anti-HSV antibodies can
bind to and neutralize the HSV directly or can coat the HSV so that it may be
opsonized by a phagocyte.

HSVs can also evade some cellular immune mechanisms. Cytotoxic T-

lymphocytes are able to bind to and kill infected cells that express HSV antigens
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and major histocompatibility complex (MHC) antigen on their cell surface (2).
However, neuronal cells do not express the MHC antigen that is required for the

cytotoxic T-lymphocyte to bind (2). Thus, latently infected neuronal cells cannot
be destroyed by these lymphocytes.

Both HSV-1 and HSV-2 are the cause of genital and orofacial infections,
and infections caused by each type are usually clinically indistinguishable.

Therefore both types of HSV are not exclusively associated with specific infection
sites, presumably because HSV-1 and 2 share 50% DNA sequence homology (1).

In the United States, most orofacial infections are caused by HSV-1 while
approximately 85% of genital infections are caused by HSV-2 (8). In Japan,

however, most genital herpes cases are caused by HSV-1 (9). Symptoms and
duration of infection are similar for HSV-1 and 2 genital infections, though

recurrences are more likely for type 2 infections (4, 6). Similarly, orofacial HSV-1
infections recur more frequently than orofacial HSV-2 infections (6). HSV-1 also

causes most eye and brain HSV infections. Infection of the brain usually results in

herpes simplex encephalitis (HSE), which is one of the rarest and most serious

diseases caused by HSV-1.

Genital herpes is the most common disease caused by HSV-2. This disease

is most often sexually transmitted, though it can be transmitted by self-inoculation

of virus from an oral or finger infection in immunosuppressed patients (4).
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Sexually transmitted HSV-2 infections may also be associated with rectal and
perianal HSV infection, especially in immunosuppressed patients whose genital

infection has spread and in people having rectal intercourse (4).

The most serious consequence of genital herpes infection in females is
neonatal herpes. Infection in the neonate may occur before, during or after the

time of delivery (10). Most infections are caused by contact with the mother’s
infected genital secretions as the baby passes through the genital tract, though

transplacental transmission, ascending infection following rupture of membranes
and postpartum infection resulting from contact with relatives or health care

workers has been known to occur (10, 11).

A rapid and sensitive technique is needed to detect HSV infection, as early

treatment can prevent fatality in people with herpes simplex encephalitis (12) as
well as disseminated disease in infected neonates and immunosuppressed patients
(13), and may ensure that effective treatment is being given to patients with less

severe infections. Current techniques are either difficult to perform, lack
sensitivity and/or specificity or take too long for an accurate diagnosis (14-17).

The objectives of this research were to evaluate two diagnostic kits for
HSV: one, a cell culture system (HSVDISK) that uses centrifugation to speed up

the infection process and an HSV specific DNA probe for detection of HSV DNA
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in the cells; and the other, an enzyme immunoassay (Surecell) that uses HSV

specific antibody to detect viral antigen in the patient specimen. To determine
sensitivity, specificity, and the ability of the Surecell and HSVDISK tests to predict
"true" HSV positives and negatives, the two tests were compared to viral isolation

by cell culture, the "gold" standard method of detecting HSV (17). At the same

time, each of the three tests were rated according to speed of HSV detection and
the ease at which the test was performed.
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LITERATURE REVIEW

General Properties of HSV

HSV-1 and HSV-2 are classified in the alpha subfamily of herpes viruses
(alphaherpesvirinae), which also includes varicella-zoster virus (18). The members

of the alphaherpesvirinae share a number of characteristics. First of all,
alphaherpesvirinae have linear, double-stranded DNA genomes which are

packaged in an icosahedral capsid. In HSV-1 and 2, this capsid is surrounded by
a protein and phospholipid tegument and an outerlying envelope that is derived

from the host cell nuclear membrane (19). Viral glycoproteins are embedded in
this envelope which function in viral attachment to the host cell membrane during
the infection process.

The second common characteristic is that viruses belonging to this

subfamily have short replication cycles (HSV replicates in approximately 18 hours)
and the site of replication is the nucleus of the infected cell (20). HSV infection

commences with attachment of the virus to receptors on the host cell followed by

fusion of the viral envelope with the host cell membrane (1). This process allows
the viral nucleocapsid to gain entry into the cell cytoplasm. The nucleocapsid is

then transported to the cell nucleus and disassembled to release viral DNA.

Subsequent expression of the viral genes needed for replication (alpha, beta, and
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gamma genes) then occurs in a sequential manner which is necessary for the

formation of an infectious viral particle (20, 21). Alpha genes are expressed
earliest, producing proteins that are used primarily to regulate expression of beta
and gamma genes. Subsequently, the beta genes are expressed which code for
regulatory proteins of gamma genes and for enzymes needed in replication of viral

DNA The structural proteins that make up the viral particle are then coded for
by the gamma genes, which are expressed last in the replication cycle. The

replicated viral DNA is then packaged in the structural proteins coded for by the
gamma genes and the resulting nucleocapsid acquires an envelope by budding

through the host cell nuclear membrane (22). Progeny virions can then infect

neighboring cells after they are transported via the endoplasmic reticulum and
Golgi apparatus to the surface of the infected cell (23). Release of the progeny

virions may or may not result in the lysis of the infected cell.

The life cycles of the various members of the alphaherpesvirinae subfamily
differ in some aspects, but the common factor is that all these viruses have the

ability to replicate in mucous membranes, skin, and neural tissues, enabling them

to infect virtually any area of the body. In order to establish infection, it is
important that the virus contact mucosal surfaces or abraded skin of the host and

also survive host immune defenses (6). Replication of the virus in infected cells
and spread of progeny virus to neighboring cells may then result in a primary

symptomatic infection, which for members of alphaherpesvirinae classically
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manifests as vesicular lesions on the skin or mucosal surface surrounding the
infected area. Primary infections with HSV, however, are most commonly

asymptomatic or so mild that symptoms are barely noticeable (1, 5).

Another characteristic of the alphaherpesvirinae subfamily is that primary

infection generally results in the establishment of latent virus in neural and dermal
tissues which surround the site of primary infection. During latency, normal

cellular activity continues to occur even in the presence of virus because the viral
genome remains in a dormant phase of growth (non-replicating) in the nucleus of
the infected cell (24-26). The virus may remain latent in an infected cell

throughout an individual’s lifetime and may become spontaneously active in
conditions of physical and emotional stress (6). Stressful factors such as excessive

sunlight, hormonal changes, and trauma can trigger reactivations by derepressing
latent viral genes (2), so that viral DNA replication and production of progeny

viruses ensues. This reactivation may result in lytic infection in which progeny
viruses are released by lysis of the infected cell or it may result in viral shedding in
which viruses are released from the cell in a slow, controlled manner without

lysing the infected cell (27). The released progeny can then infect neighboring
cells or can be transported along neuronal axons to a new site where latent or

active infection may be established (2). Symptoms produced during active
recurrent infection at the same or a new site are generally less severe, more
localized to the reinfection site, and are shorter in duration than the symptomatic
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primary episode (4, 5, 28). This is presumably due to immunity acquired as a

result of primary infection (2). In most cases, reactivation of virus from latently
infected cells does not lead to a symptomatic recurrence of infection, as these

viruses are usually eliminated by host immune defense (29, 30). However if host
immune defense is suppressed, as is the case for many cancer and AIDS patients

or other persons on immunosuppressive therapy, these symptomatic recurrences
are typically more frequent and severe (31). Thus host immune status primarily

determines the frequency and severity of symptomatic recurrences (31).

Unfortunately the physical and emotional stresses that trigger reactivations also
suppress host defense mechanisms against the virus (2), so that during times of

stress, even immunocompetent hosts are more likely to experience a symptomatic

recurrence.

Host Response to HSV

The various types of responses elicited by the host during an HSV infection

include local, cellular, and humoral immune defense. HSV cannot normally
penetrate intact skin, however, injured skin, mucous membranes, and conjunctiva

are more susceptible (6). Nonspecific effectors such as macrophages, monocytes,
and polymorphonuclear leukocytes (PMNs) are important in both the innate and

acquired immune response to HSV infection (32). These cells can eliminate both

extracellular and intracellular virus by phagocytosis, which can occur with or
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without the help of anti-HSV antibodies (33). Macrophages also act as antigen
presenting cells (APCs) by processing HSV and presenting HSV antigen to a B- or
T-lymphocyte so that the antigen’s effectiveness as an immunologic stimulus may

be increased (34). APCs thus serve to prime the immune system so that immune

response is much faster upon subsequent exposure to the antigen.

Initial encounter with HSV causes the proliferation and differentiation of

specific B- and T-cell clones. Some of the progeny lymphocytes become the
effector cells that produce the primary immune response, while others become

memory cells which serve in eliciting a faster immune response during a secondary
HSV exposure. B-cell derived effector cells are plasma cells which produce and

secrete specific anti-HSV antibodies that can neutralize extracellular virus and
bind to infected cells so that the infected cells may be opsonized (33). T-cell

derived effector cells (T cytotoxic, helper, or suppressor cells) help eliminate

extracellular HSV and HSV infected cells through the production of soluble
factors called cytokines (35, 36). Contact of a primed T effector cell with HSV
antigen stimulates the release of cytokines which can have several effects. The

released cytokines can act to 1) neutralize extracellular HSV directly, 2) lyse an
HSV infected cell by causing perforations in the host cell membrane, or 3) cause

proliferation and migration of other effector cells (such as macrophages) at/to the

site of infection (32). Various in vitro studies have shown that the production of
the cytokines, interleukin-2 (35, 36), alpha-interferon (37), and interleukin-7 (38)
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by antigen activated T helper cells is necessary for cytotoxic T-lymphocyte lysing of

HSV infected cells. Cytokines can also be produced by other immune cells such

as macrophages, PMNs, and NK cells. The cytokines produced by these cells may
act on the same type of cell or on other immune cells to ultimately produce an
anti-HSV response. Interferon, for example, whether produced by macrophages

or T-lymphocytes, causes pleiotropic effects on macrophages (32). In addition,

exogenous alpha- and gamma- interferon appears to inhibit HSV-1 genes encoding
early gene products in spleen macrophages of mice (39, 40). Thus interferon not

only causes proliferation and migration of macrophages to the infected site but
also is able to prevent replication of HSV-1 in infected spleen macrophages of

mice. Indeed the role of cytokines in immune defense against herpes simplex

viruses has not been fully elucidated.

In addition to effector cells, clones of memory B- and T-cells are produced

as a result of the initial encounter with HSV. Upon subsequent exposure to HSV
antigen, such as in the case of reactivated virus or exposure to another viral strain,

these memory B- and T-cells produce a faster and more efficient immune
response. This is accomplished by the immediate transformation of memory B
cells into plasma cells that produce an increased amount of antibody and

proliferate forming other identical plasma cells and/or other memory B-cells. A
similar process occurs with the memory T-cells, with these cells producing Thelper, suppressor and cytotoxic cell clones.
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Host defense mechanisms against HSV are not capable of completely

eliminating HSV from an infected body, making HSV infection a lifelong threat.

Certain characteristics in the HSV life cycle enable HSVs to avoid destruction by
certain humoral and cell-mediated immune activities. First, progeny HSVs may

spread directly from cell to cell during the infection process, bypassing host
defense mechanisms that are only able to eliminate extracellular virus (including

destruction via antibody neutralization, and by opsonization and other phagocytic
mechanism requiring extracellular virus) (7). Secondly, HSVs can avoid

destruction by the complement cascade, a series of enzymes (C1-C9) found in
blood serum that can sequentially bind to and lyse an infected cell by making a

hole in the cell membrane. HSVs produce a C3-binding molecule, glycoprotein
Cl, which can cause decay of the C3 convertases of the classical and alternative

pathways of the complement cascade (41). Thus the complement cascade does

not provide protection against HSVs that express surface glycoprotein Cl. HSV

strains and HSV infected cells that do not express the glycoprotein Cl, however,
are susceptible to complement mediated cell lysis and viral neutralization (42).

Thirdly, HSVs remain latent in neural cells which are not able to be killed by

cytotoxic mechanisms due to the inability of cytotoxic T-lymphocytes to recognize

and bind to cells that don’t express MHC antigen (43). Despite the viruses ability
to evade destruction by these methods, both humoral and cell-mediated immune

mechanisms help to keep HSV infection localized and shorten the duration of
infection (1). Thus viral replication is inhibited by humoral and cellular immunity,
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but these immune mechanisms cannot prevent establishment of latency or viral

reactivation which may lead to recurrent infection.

Antibody-dependent cellular cytotoxic (ADCC) activities which use both

humoral and cellular immune mechanisms have also been shown to slow down
viral replication. ADCC involves the cytotoxic activity of natural killer (NK) cells

or some other leukocytes. During this process, the infected cell is coated with
anti-HSV antibodies which bind to the viral antigens expressed on the cell’s

surface. NK cells have receptors that can bind the Fc portion of the antibodies,
so that the NK cell may contact the infected cell. This contact triggers the release
of proteins called perforins which destroy the infected cell by making holes in the

cell membrane (44, 45).

Because of the numerous activities involved in controlling HSV infection, it

is hard to determine the relative contribution of humoral and cell-mediated
immune mechanisms (46). Most of what is known about cell mediated immunity

(CMI), for instance, comes from animal and human tissue culture studies which
may not accurately portray CMI in vivo (46). CMI does seems to be of chief

importance in limiting infection and maintaining latency, since patients with

depressed CMI, such as people with AIDS, chronic eczema, and cancer, have

more frequent and severe infections (1, 13, 47). Reactivated virus is not removed

as effectively in these patients as it is in immunocompetent or
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agammaglobulinemic individuals (1, 6).

Clinical Scope of HSV infection

Based on seroepidemiologic data, HSV-1 infections have been shown to
occur in 50-100 percent of adults, depending largely on socioeconomic status (4).

HSV-1 infections in persons of lower socioeconomic status are more prevalent and
generally occur at an earlier age (6). Since HSV-2 is usually acquired as a
sexually transmitted disease, antibodies against HSV-2 don’t usually appear until

after adolescence. Studies have shown anywhere from 0.3 to 22% of adults in the
United States have anti-HSV-2 antibodies (6, 30, 48, 49). Prevalence of

seropositivity depends on age, sex, race, socioeconomic status, and sexual history

of the individual (30, 48, 49).

Most primary infections with HSV-1 are asymptomatic, but may be

followed by recurring clinically active infections (1, 5). Gingivostomatitis and
pharyngitis are the most common symptomatic primary HSV-1 infections, while
herpes labialis, or cold sores, is the most common recurrent HSV-1 infection (1).
Clinical symptoms of gingivostomatitis and pharyngitis include vesicular or

ulcerative lesions of the oropharynx and face accompanied by fever, malaise, and
irritability. Recurrent infections of this type are referred to as cold sores or fever
blisters, and are typically milder and more localized. The primary infection most
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often occurs before the age of 5 (5), but since most of these infections are
asymptomatic most people experience the recurrent infection (cold sores/fever

blisters) without ever having gingivostomatitis.

Infection of the eye with HSV-1 is a common cause of corneal blindness

(50, 51). Primary and recurrent eye infection typically result in

keratoconjunctivitis which is characterized by lesions surrounding the eye.
However, recurring infections may also result in the formation of dendritic ulcers.

Recurrences involving corneal stroma can lead to loss or impairment of vision (50,
51).

HSV-1 is responsible for most skin infections. Two common HSV skin

infections include herpetic whitlow and eczema herpeticum. Herpetic whitlow is
caused by inoculation of HSV into a cut or sore on the hand (52) which results in

vesicular lesions on the fingers. This disease occurs primarily in health care

workers and thumb sucking children (53, 54). Eczema herpeticum occurs most

frequently in people with chronic skin disorders. This disease results from
inoculation of virus into skin lesions associated with eczema, which produces large
vesicular lesions at the site of infection. These lesions are often fragile and burst,

leaving the skin unprotected (4). Infection in these patients may rapidly spread
covering extensive areas of the skin and may even disseminate to visceral organs.
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Herpes simplex encephalitis (HSE) is the rarest and most serious disease

caused by HSV-1. This disease occurs predominantly in patients aged 5-30 and
over 50 and may be the result of primary infection or recurrent infection (55).
HSE results from transmission of virus from the periphery up the olfactory bulb to

the brain or from reactivation of latent virus in nerve root ganglia with spread of

infection to the brain (56). Fever, headache, neurological problems associated

with temporal lobe, and other non-specific clinical symptoms make diagnosis of
HSE difficult. Untreated mortality rate is over 70%, and even with antiviral
therapy, neurologic sequelae usually occurs (4, 57).

The most common disease caused by HSV-2 is genital herpes. Over

500,000 new cases of symptomatic primary genital herpes and over 10,000,000

symptomatic recurrences occur yearly in the United States (30). Primary
symptomatic episodes of genital herpes last an average of three weeks and are

characterized by painful vesicular lesions covering the external genitalia, buttocks,
cervix and urethra. These lesions may accompany dysuria, fever, headache,
malaise, genital itching and discharge, and tender lymph nodes (1). Prior HSV-1

infection seems to lend partial immunity to HSV-2 genital infections, as these

patients have less frequent symptoms and faster healing with the primary episode
(5). The highest incidence of primary symptomatic genital infection occurs in
people age 20-30 (6).
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Aseptic meningitis may be associated with primary genital HSV infection.
Though rare, HSV may ascend to the spinal cord, where further replication can

lead to aseptic meningitis (58). The disease course is self-limiting, but since latent

infection may be established, recurrences may occur (59).

The most serious consequence of genital herpes infection is neonatal

herpes. Infection in the neonate may occur before, during, or after the time of

delivery (10). Currently, cesarean section is recommended if active maternal

infection is present, but most women who deliver infants who get HSV infections
are asymptomatic at the time of delivery (60, 61). Not all infants who are exposed

to the virus around the time of delivery will acquire a herpes infection (62, 63).
Being born to a mother with primary genital infection poses the greatest risk to
the infant (64). Half the infants born to a mother with primary infection will

develop an HSV infection, while only 4% born to mothers with recurrent infection
will develop infection (64). Moreover, infants born to a mother with a primary

genital infection more often develop disseminated infection, while infants born to

a mother with a recurrent infection typically only develop skin, eye, or mouth
lesions or localized encephalitis (63, 65). These differences are probably due to

immunity acquired transplacentally from the mother in infants born to mothers

with recurrent infections (65, 66). Disseminated herpes usually presents as a

sepsis-like illness with fever and perhaps even the appearance of skin, eye, or
mouth lesions (62). Other complications such as necrosis of the liver and adrenal
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glands, thrombocytopenia, meningoencephalitis or pneumonia may develop (67).
Incidence of infection has been estimated to range from 1 in 7500 to 1 in 30,000
births (68). Of these infected neonates, approximately 65% will die (4, 57) and

those that live will most likely develop severe neurologic sequelae (67).

Unfortunately, reactivation of HSV-2 infection is more common in pregnant
women than in other women (69) and at least 20% of pregnant women have had

prior HSV-2 infection (10, 70).

Due to the increased number of AIDS cases and the widespread

administration of immunosuppressive therapy for transplants, cancer, and other
diseases, the number of severe cases of HSV infection has increased during recent
years (4). Patients undergoing such therapy can be subjected to frequent and

severe reactivations of HSV infection. These recurrences of HSV infection may

be associated with prolonged viral excretion and chronic lesions in these patients.

These lesions can result in extensive tissue necrosis and though rare, may even
lead to viremia and dissemination through multiple organs (28). Diseases such as

meningoencephalitis, pneumonitis, hepatitis, coagulopathy, esophagitis, and

proctitis may occur as a result of dissemination (1).

Therapy for HSV infections

Acyclovir, an antiviral therapeutic agent, is typically administered for both
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immunocompetent and immunosuppressed patients (13, 71). Treatment of
immunosuppressed patients is usually started at first sign of HSV infection, even
without culture confirmation of infection (13). Early treatment is imperative in

these patients as HSV infection can be life threatening. Persons with AIDS

however may develop resistance to acyclovir (13, 72). Vidarabine is an effective
alternative to acyclovir therapy, however, this drug is not as efficient as acyclovir
in fighting mucocutaneous HSV infection (73).

Laboratory Detection of HSV infections

The discovery of effective anti-HSV drugs has prompted the need for more
rapid and sensitive HSV diagnostic tests in recent years. Early diagnosis and
treatment ensures better patient prognosis, puts the patient at ease to receive

reliable information on management and prognosis, ensures the doctor that proper
treatment is being given, and decreases cost of health care by limiting patient

hospital stay and eliminating the expense associated with unnecessary testing and

treatment. HSV tests currently available to clinical laboratories either lack
sensitivity or specificity, are tedious to perform, or take too long for an accurate

diagnosis.

The most common methods for diagnosing herpes presently include viral
isolation by cell culture, detection of HSV antigens by a variety of immunologic
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techniques such as enzyme-linked immunosorbent assays, enzyme immunoassays,

immunoperoxidase staining, and immunofluorescence staining, and demonstration

of amplified or non-amplified HSV DNA using various DNA hybridization

methods (14, 16, 17).

Virus isolation by cell culture used with another method for confirmation of
HSV-caused cytopathic effect (CPE) is the most sensitive, specific and widely used

technique to date (74). Immunofluorescence staining is most commonly used to
confirm HSV-caused CPE, however other confirmation techniques such as
immunoperoxidase staining, ELISAs, EIAs, or DNA probe hybridization may be

used. Even though cell culture is still considered the "gold standard" for HSV

detection, this method often takes too long to detect infection, requires expertise,

and may be affected by toxic components in the patient specimen. CPE takes an
average of three days and may take as long as eight days to appear if low numbers
of the virus are present (14, 17). A more rapid diagnosis is needed to test

pregnant women near delivery for asymptomatic shedding of the virus (10), to

ensure rapid treatment of neonates, immunocompromised patients, and persons

with HSE for whom dissemination of HSV infection may be fatal (31, 60, 75), and
to ensure that proper treatment is being given in cases where treatment has been

initiated without clinical confirmation of the infection as being caused by HSV.
Cell culture also requires technical expertise for recognition of CPE and
maintenance of the culture (74, 76). The expert must be trained in distinguishing
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CPE caused by HSV and CPE caused by other viruses in order to perform the
appropriate confirmation test. As a result of this, many hospitals and clinics send

the clinical specimens to a virological laboratory for expert recognition of CPE,
further delaying detection of the disease because of transport time. Another
problem with cell culture is that toxic components in the specimen may also cause
cell deterioration after a three to ten day incubation period (14, 76), making

microscopic examination of the cells for CPE caused by HSV hard to interpret.

Corey reported four cases in which toxic components in the rectal specimens of
infants caused false positives in cell culture (14). The infants were immediately

hospitalized and treated for HSV infection costing the hospital 10,000 dollars per
infant, only to find out that repeat specimens taken from the infants were negative

(14). Confirmation of HSV CPE by using a technique such as
immunofluorescence staining of cells has reduced the chance of this occurring,

however some labs still rely on cell culture alone to determine infection by the
virus. Though cell culture used in conjunction with an immunologic confirmation

technique is currently the most accurate and widely used technique today, a more
rapid, inexpensive, and more easily managed technique would be beneficial to the
patient and hospital or clinic. Moreover, cell culture detection of HSV is not

practical for small community hospitals or clinics that receive only a small number
of patient specimens to be tested for herpes, as cell culture can be expensive and

laborious to maintain.

Many of these hospitals or clinics only receive a few

specimens per week if any and staffing is not appropriate to perform such testing.
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Immunofluorescence, immunoperoxidase staining, immunoassays such as

ELISA and EIA, and DNA hybridization techniques can be used alone (without
cell culture) for detecting HSV in clinical specimens (14, 16). The main advantage

of these techniques is that they are generally much faster and easier than HSV
isolation by cell culture, but when used alone, these tests have generally shown

lower sensitivities and specificities than cell culture (14, 15). Studies involving
direct immunoperoxidase staining of specimens scraped from lesions have shown

sensitivities of about 80% in comparison to cell culture used without a
confirmation test (77-80). Because of the low sensitivity associated with direct

immunoperoxidase staining of specimens, immunoperoxidase staining is generally

only used to verily HSV isolates from cell culture (77, 80, 81).

Another problem

with this technique being used alone to directly detect HSV in the patient
specimen is that a negative result is reliable only if the sample specimen contains

intact cells. Schmidt and coworkers reported that out of 180 specimens, 23
contained insufficient cells to permit valid interpretation of results (77). Thus the

laboratory must confirm the adequacy of the specimen before processing it and
specimens must be reacquired if they are unsatisfactory (77). Kits that combine
cell culture with immunoperoxidase staining for the detection of HSV have found

staining of cells at 48 hours to be less sensitive than standard cell culturing
confirmed by immunofluorescence staining (82-85). Immunofluorescence and

immunoperoxidase staining have, however, exhibited similar sensitivities in

confirming an HSV isolate after CPE was observed in cell culture (77, 82).

22

Sensitivities of ELISAs and EIAs range from 35 to 100% of that obtained
by cell culture, depending on whether the CPE in cell culture is confirmed by

another immunologic method (86-95). Specificities of immunoassays have been
nearly equivalent however to those of cell culture (86-89, 94-96). The fact that
results can be obtained in a few minutes to up to six hours using immunoassays

warrants the use of these techniques for emergency diagnosis in case of suspected
neonatal infection or infection in the immunocompromised (14, 86). However

since this technique involves detection of viral antigen, a positive result is not
necessarily synonymous with active infection of HSV (88), and false positives can

sometimes occur due to non-specific binding of antibody (88, 94). At the present
time, EIAs and ELISAs are most commonly used in combination with viral

isolation by cell culture to verify a positive or negative result (89, 94, 97), or as a
screening test for positives (89, 95) since specimens producing negative

ELISA/EIA results are usually tested by cell culture as a backup.

A number of reports have shown immunofluorescence staining to be a less
sensitive method than viral isolation by cell culture (98-103), although this method

seems to be ideal for confirmation of HSV isolated by cell culture (104). In a
long term study comparing immunofluorescence staining with monoclonal
antibodies to viral isolation by cell culture in patients with recurrent genital

herpes, Lafferty and coworkers (100) reported an overall sensitivity and specificity

of 74 and 83%, respectively, in comparison to when both cell culture and
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immunofluorescence staining were used. However viral isolation by cell culture

and the immunofluorescence staining technique when used alone had similar
sensitivities (53 and 51%, respectively) for the initial sample received from the

patient (100). Thus to maximize laboratory confirmation of HSV infection on a
single visit by a patient, Lafferty and coworkers suggest that using just

immunofluorescence staining or viral isolation by cell culture is not sufficient

(100). In a similar experiment by Pouletty and coworkers (101),
immunofluorescence assays using monoclonal antibodies were performed on 652

specimens directly. This method showed a sensitivity of 84.6% in comparison to
viral isolation by cell culture, however, for one patient, only one of three

specimens gave a positive result (101). Numerous investigators have suggested
that these false negatives may be due to the quality of the specimen sample (98,

100-102). Nerurkar reported problems in distinguishing negatives from positives
when a specimen smear was dried or stored too long before staining and when

nonspecific intense staining of debris in the specimen cells occurred (102). Thus

in addition to the decreased sensitivity of this method in comparison to cell culture
with confirmatory immunofluorescence staining, specimen quality and preparation

may be a hindrance in obtaining a correct positive or negative result. Although
immunologic methods used in conjunction with virus isolation by cell culture seems

to be the most sensitive and rapid way of obtaining an accurate result, the
ultimate goal for HSV diagnosis is to have a single test that is rapid, sensitive,
reliable, simple and inexpensive.

24

HSV infection may also be detected by demonstration of nonamplified
HSV DNA using DNA probe hybridization. Probes can be labeled with enzyme

or radioisotope and are usually added to the specimen sample directly (105-107).

Using DNA probe hybridization has proven to be very rapid and convenient,

however, the sensitivity and specificity of the probes used thus far to detect HSV
DNA in a specimen seem to vary greatly and thus produce unpredictable results

(105-107). In one experiment by Langerberg and coworkers (105), the sensitivity
and specificity of a test using a biotinylated HSV DNA probe was compared to

viral isolation by cell culture with immunofluorescence staining confirmation. The
sensitivity and specificity of the test for detecting HSV was determined to be 92%

and 63% to that of cell culture, respectively. Similarly, Fung and coworkers (106)
reported a sensitivity of only 71.4% and a specificity of 90.6% for a biotinylated

probe in comparison with cell culture used with immunofluorescence staining
confirmation. The disparity in these results may be indicative of the

unpredictability of this method. Furthermore Langenberg and coworkers (105)
reported that the sensitivity of this method dropped to 57% that of cell culture

with IF staining if a specimen of less than 20 cells was evaluated. Apparently, the
sensitivity of the HSV DNA probe decreases dramatically at low virus
concentrations (106). Another drawback to this method is that some DNA probes

exhibit non-specific cytoplasmic binding (106, 107) when added directly to patient
specimens, and thus may give a false positive reading. Fung and coworkers found

that 27.2% of the specimens tested exhibited non-specific cytoplasmic staining with
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an HSV DNA probe (106). Because of the unpredictable sensitivity and
specificity of these DNA hybridization tests, they have thus far only been used in

conjunction with viral isolation by cell culture in determining if a patient is
infected with HSV.

More recently, probes have been used to detect amplified sequences of

HSV DNA in the patient specimen directly using polymerase chain reaction

(PCR), however, current problems with PCR such as carry-over of amplified

products and requirement of specimen purity (16) make it hard to predict when
this test will be able to be performed routinely in the clinical laboratory (15).
Studies that have used this technique to determine the presence of HSV in clinical

specimens generally report an equal or higher sensitivity for PCR as compared to
cell culture (108-112), however, some of the results regarding patients whose

specimens were positive by PCR but negative by cell culture weren’t conclusive as

to whether the patient was experiencing an active infection (108, 111). Methods
that use cell culture for the detection of HSV have an advantage in that only
actively infecting virus will be detected. At the present time there is no clinically

available PCR technique that can distinguish between a latent and an active HSV

infection (16); previous studies using PCR to detect HSV have made diagnosis of

active or latent infection based on the clinical status of the patient (16, 108, 110).
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Study Method

In this research two currently available kits, Diagnostic Hybrids
HSVDISK™ and Kodak’s Surecell, were evaluated and compared to results with

cell culture for detection of HSV in clinical specimens. Diagnostic Hybrid’s
HSVDISK is a test kit for the culture and detection of HSV by in situ DNA probe

hybridization. This method combines amplification of viruses by cell culture and

detection of the viruses using in situ DNA probe hybridization after only 24 hours
as compared to a 1-8 day diagnosis when using standard cell culture. This method
has one advantage over other DNA probe hybridization methods in that viral

numbers are amplified before detection, so clinical specimens containing only a
few intact cells are not a concern. The 24-well cell culture trays are easier to

handle than individual cell culture shell vials. The number of wells containing cell

monolayers can also be varied according to the needs of the hospital or clinic.
Thus as many as 11 patient specimens can be tested on one tray. Kodak’s
Surecell is a monoclonal antibody-based enzyme immunoassay that detects HSV

antigen from patient specimen in under fifteen minutes, making it an appealing

rapid test in cases where quick confirmation of HSV infection is needed. Since
the Surecell assay detects HSV antigen, active HSV need not be present in patient

specimen in order for a positive result to be obtained. The Surecell assay would

thus be particularly useful in detecting HSV in late stage lesions which
characteristically contain low titers of HSV. The Surecell test tray comes with
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built-in positive and negative control wells and accommodates only one patient
specimen per tray. Thus the Surecell assay would be most appealing to hospitals,

clinics, and doctor’s offices that rarely receive clinical specimens to be tested for
HSV.
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MATERIALS AND METHODS

Specimen Collection

Specimens were obtained from both asymptomatic and symptomatic
patients from St. Elizabeth’s Medical Center, Dayton, Ohio. It was not known if
the patients had ever experienced a prior HSV infection. All specimens from

asymptomatic patients were collected from the hospital’s obstetrical-gynecological

clinic. These patients were either pregnant or in their childbearing years.

A total of 154 specimens were analyzed, including 142 genital specimens
and 12 specimens from other sites such as skin, esophagus, and abdomen. Of the

154 patient specimens collected for the study, 40 were tested by standard cell

culture, HSVDISK, and Surecell, 2 were tested by cell culture and Surecell only,

and 112 were tested by cell culture and HSVDISK only. When available, age, sex,
and clinical presentation of each patient was also recorded.

Specimens from active lesions were collected with sterile cotton swabs, and

those from asymptomatic patients were collected by swabbing the cervix and/or

vagina. All swabs collected were placed into viral transport medium consisting of
approximately 1.8 mis of minimum essential medium with 10% fetal bovine serum

and 10 /zg/ml gentamicin. A portion of each specimen was sent to a virological
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laboratory (Diagnostic Virology Services, Inc., Centerville, Ohio) to be tested by

cell culture, while the other portion was reserved to perform the HSVDISK™
and/or the Surecell test(s) at St. Elizabeth microbiology lab. The swab from each

specimen was reserved for use in the Surecell test. The HSVDISK™ test was
performed within 48 hours of specimen receipt or the specimen was frozen at -

70°C and tested at a later time. Surecell and cell culture tests were performed
within 24 hours of specimen receipt.

Cell Culture Method

Cell culturing at the reference laboratory was performed by inoculation of
the patient specimen onto triplicate African Green Monkey Kidney cells. The
cells were then centrifuged to allow absorption of virus present in the patient

specimen onto the cell monolayer and incubated at 37°C in 5% CO2. Cultures

were observed daily for 10 days for CPE. If CPE did not occur within this time
period, cultures were considered negative. Immunofluorescence staining of the

cells was used to confirm CPE caused by HSV.

HSVDISK™ method

HSVDISK kits were obtained from Diagnostic Hybrids, Inc., Athens, Ohio.

The HSVDISK kit includes 24-well culture plates containing African Green
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Monkey Kidney Cells (CV-1), replacement medium, blocking solution, fixative

solution, wash solution, chromogenic substrate solution, and probe hybridization
solution. Positive controls were not provided. The probe hybridization solution

contains a single stranded HSV-1 and -2 specific DNA probe linked to alkaline

phosphatase in a buffer solution containing 25% formamide. The probe is 2-kb in
length and includes 800- and 1,200-bp Pstl discontiguous regions of DNA from

HSV strain IF that are cloned in the M13mpl9 bacteriophage (113).

Cell culture plates containing African Green Monkey Kidney Cells (CV-1)
were maintained using kit replacement medium consisting of minimum essential
medium supplemented with 10% fetal bovine serum and 10 /zg/ml gentamicin.

Cell monolayers were inoculated with 0.2 ml of patient specimen eluate per well,
centrifuged at 700 x g for 10 minutes at room temperature to allow absorption of

virus to cell monolayers, and incubated at 35-37°C in a humidified 5% CO2
atmosphere for 24 hours. One positive and one negative control well were

included on each plate. HSV-2 strain G and HSV-1 strain F obtained from
American Type Culture Collection (Rockville, Md.) were used as positive controls.

At 24 hours, cell monolayers were submerged in 95% ethanol for 5 minutes
after which 0.25 ml of blocking solution consisting of neutralized triethanolamine

containing 0.05% sodium azide was added to each well for 5 minutes to reduce
nonspecific background staining. The cell monolayers were fixed and the DNA

31

denatured with 0.25 ml of fixative solution containing ethanol and sodium

hydroxide. Alkaline phosphatase labeled HSV DNA probe hybridization solution
(0.25 ml) was added to each well and the plate incubated in a 45°C water bath for
30 minutes. The plate was washed three times with wash solution made of

phosphate buffered saline and incubated with wash solution for 10 minutes at
45°C. To develop color, 0.25 ml chromogenic substrate solution containing

dimethylformamide, bromochloroindolyl, and nitrotetrazolium blue was added to

each well and the plate placed in a 45°C water bath for 60 minutes. The wells
were washed with distilled water and each well examined for stained cells at 40

and 100X using an inverted light microscope. A positive result was indicated by

> 10 cells in the monolayer whose nuclei are stained purple.

Surecell method

Surecell kits were obtained from Eastman Kodak Company, Rochester,

New York. The Surecell kit includes a test cell with three wells (negative control,
positive control, and patient specimen well), extraction buffer, three wash

solutions, peroxide solution, negative control conjugate, antibody conjugate, leuco

dye solution, extraction tubes and filter tips.

The Surecell test is able to detect HSV-1 or -2 directly from patient swabs

or in patient swabs placed in viral transport medium. All specimens in this study
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were tested after placement of the swab in viral transport medium. HSV-specific

antigens, if present in the patient specimen, are extracted by placing the swab, 0.5

ml of the viral transport medium, and 0.5 ml of extraction buffer into an

extraction tube. The swab was rotated for one minute in the extraction solution to
release HSV-specific antigens and then discarded. A filter tip was attached to the
tube and equal aliquots of solution were filtered into the three test cell wells.

Each well contains one filter membrane and an underlying absorbent pad so as
the filtrate is drained through the wells, any HSV-specific antigen present in the
filtrate binds to the filter membrane present at the bottom of the well. To

eliminate non-specific binding reactions, each of the three wells were rinsed with
buffered wash solution followed by hydrogen peroxide solution. The negative
control conjugate containing non-HSV specific monoclonal antibodies was then
added to the negative control well and the HSV-specific monoclonal antibody

conjugate was added to the positive control and patient wells. After five minutes,

the wells were rinsed and a leuco dye solution was added to develop color.
Presence of a uniform pink color in the patient and positive control wells, but not
in the negative control well, indicated a positive result.

Statistical Analysis

Calculations of sensitivity, specificity, and positive and negative predictive

values for the HSVDISK and Surecell assays were made in comparison to the
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standard cell culture method, which was assumed to be 100% accurate in the
determination of whether a patient specimen was positive or negative. The
calculations were as follows:

Sensitivity =

true positives______
true positives + false negatives

X 100

Specificity =

true negatives______
true negatives + false positives

X 100

Positive Predictive Value =

true positives
all positives

Negative Predictive Value = true negatives
all negatives
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X 100

X 100

RESULTS

HSV Detection in Clinical Specimens

One hundred fifty four specimens collected from patients of St. Elizabeth

Medical Center were analyzed for presence of HSV. Of these, 131 were cervical
and/or vaginal cultures, 11 were penis cultures, and 12 cultures were from other

sites such as skin, esophagus, stomach and abdomen. Sixty-five specimens were

taken from patients experiencing symptoms suggestive of an HSV infection

(symptomatic), while 89 were from patients showing no signs of HSV infection
(asymptomatic). All specimens taken from asymptomatic patients were cervical

and/or vaginal cultures.

Of the 154 patient specimens collected for the study, 40 were tested by
standard cell culture, HSVDISK, and Surecell, 2 were tested by cell culture and

Surecell only, and 112 were tested by cell culture and HSVDISK only. To assess

their overall performance for detecting HSV in clinical specimens, the results from

the Surecell and HSVDISK assays were compared to standard cell culture, the
"gold standard" method of detecting HSV. Table 1 shows the comparison of
results obtained for the 152 specimens tested by the HSVDISK and cell culture
assays, while Table 2 shows the comparison of results obtained for the 42

specimens tested by the Surecell and cell culture assays. There was disagreement

35

in results for 3/152 specimens tested by the HSVDISK and cell culture assays
(Table 1) and for 5/42 specimens tested by the Surecell and cell culture assays
(Table 2). Thus there was concordance in results for 98% of the specimens

subjected to the HSVDISK and standard cell culture methods, whereas 88.0% of
the results obtained by the Surecell method agreed with the results determined by

cell culture.

HSV was isolated by standard cell culture in 23 of the 154 specimens.

Incidence of herpetic infection in the overall population based on standard cell

culture analysis was thus 14.9%. Only one of the positives by cell culture came
from an asymptomatic patient. The HSVDISK method detected herpes simplex

virus in 21/152 and the Surecell method detected HSV in 12/42.

Performance of HSVDISK and Surecell

The sensitivity, specificity, positive and negative predictive values were
calculated to assess the effectiveness of the HSVDISK and Surecell tests in

detecting HSV in clinical specimens. Calculations of sensitivity, specificity, and
positive and negative predictive values for the HSVDISK and Surecell assays were

made in comparison to the standard cell culture method, which was assumed to be
100% accurate in the determination of whether a patient specimen was positive or

negative. Table 3 shows the sensitivity, specificity, positive and negative predictive
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values calculated for the HSVDISK and Surecell tests. Both the HSVDISK and

the Surecell tests exhibited similar sensitivities of detecting HSV (90.9% and
88.9%, respectively), though the ability of the Surecell test to predict true positives

was much lower (66.6%) than that for the HSVDISK test (95.2%). The

HSVDISK test was 99.2% as specific as standard cell culture in detecting HSV in
clinical specimens, whereas the specificity of the Surecell test was 87.9% that of

cell culture.

Detection times of each of the tests studied were also compared. Results

could be reported for the Surecell assay within 15 minutes and for the HSVDISK
assay in one day. Positive results by standard cell culture were reported between

1 and 4 days. The average detection time for a positive result by standard cell
culture was 2.2 days. Table 4 gives the times to detection for the positives by cell
culture. 30.4% of cell culture positives were detected as positive in one day,
65.2% were detected positive in 2 days, 82.6% were detected in three days, and
100% were detected by the fourth day. Two specimens, a skin and an abdominal

fluid specimen, were found positive by standard cell culture but negative by the
HSVDISK assay. CPE was detected on day 2 for the skin specimen and on day 4

for the abdominal fluid specimen. The abdominal fluid specimen was also found

negative by the Surecell assay.
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Patient Population

Incidences of herpetic infection in the symptomatic and asymptomatic

subpopulations were also calculated. Of the 65 patients (18 males, 52 females)
who were known to be symptomatic, there was an overall incidence of active

herpetic infection in the population of 22/65 (33.8%). This value is comparable to
those found in similar symptomatic patient populations (96, 114). Only one of the

89 asymptomatic, obstetrical/ gynecological patients tested positive for HSV by cell
culture. Incidence of active herpetic infection in the asymptomatic population was

thus 1.1%.

Since most of the specimens obtained in this study came from genital sites,
an assessment of the incidence of genital herpes infection and the ages at which

the patients experienced the genital infection was also made. Of the 142 genital
specimens, twenty were found positive by cell culture. The other three non-genital

cell culture positives included a wound, an abdominal fluid, and a gastric fluid
specimen. Eighteen of the 20 positive genital cultures were taken from females.

All positive female genital specimens came from women between the ages of 14
and 30, while the two positive male specimens came from 18 and 28 year old

males. The mean age of persons experiencing a herpes genitalis infection as
confirmed by cell culture was 20.6 +. 2.96 with an age range of 14-30. Two of

these patients were known to have a history of herpes infection.
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Four of the genital cultures found positive were taken from symptomatic
pregnant women. Symptoms in two of the women included hyperemesis

gravidarium (excessive morning sickness) for the woman who was 21 weeks
pregnant and vaginal drainage for the women who was 24 weeks pregnant.

Herpetic lesions were observed at delivery in the two other cases. One of the
women, who had a herpetic lesion on her right thigh, delivered prematurely
because of ruptured membranes at 24 weeks. It was unknown if any of the infants
were affected by neonatal herpes infection.
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DISCUSSION

The HSVDISK DNA probe assay exhibited a number of visually-distinct

types of positive reactions depending on the extent of infection of the cell
monolayer. In the majority of the clinical isolates, a positive reaction was

determined by the observance of a focal cluster of cells with nuclei stained purple.
These foci would most often be accompanied by signs of CPE (e.g., syncytia

formation and holes in the cell monolayer). Some patient wells possessed as few

as two purple foci, though results from specimens containing a high titer of virus
showed considerable cell destruction and detachment. There was no problem in

determining whether a patient result was positive or negative, despite the fact that
some positives looked different than others. In addition, no background staining

due to non-specificity of the probe or loss of purple stain due to high cellular
toxicity occurred, as was previously reported (115).

In the Surecell EIA test, there were difficulties in interpreting a result when

there was a low amount of or non-specific deposition of pink dye on the filter
membrane. Instructions provided by Kodak suggest that a patient specimen is
positive for the presence of HSV antigen if a uniform pink color in the patient

well is greater than the color found in the negative control well. For 4 of the total
42 specimens analyzed by this method, it was difficult to determine if the patient

well a)was uniformly colored with the pink dye or b)was more pink than the
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negative control well. Two of the four were most likely false positive results, as
the color in each patient well was very light pink and the cell culture assay and
HSVDISK assay results were negative. The remaining two results agreed with the

results obtained by the HSVDISK assay and the cell culture assay, despite the

difficulty that was encountered in interpreting these results.

The cell culture and HSVDISK methods reported different results for three

specimens, all of which came from symptomatic patients. One abdominal fluid

specimen and one skin specimen were found to be negative by the HSVDISK
assay but positive by standard cell culture. The abdominal fluid specimen found

negative by HSVDISK was positive by cell culture on day 4. The four day

detection period required by cell culture suggests that the HSVDISK result was

most likely a false negative due to a low titer of infectious virus in the patient’s
specimen. The Surecell result for this particular specimen, however, was also

negative. Thus there is the possibility that the cell culture may have been

contaminated by carryover of HSV, but such contaminations are not likely.
Nevertheless, the HSVDISK assay was successful in detecting HSV in three other

specimens that took 4 days for cell culture to detect.

The HSVDISK result for the skin specimen was most likely a false negative
result also, as this specimen had been frozen for 17 days prior to HSVDISK
testing and freezing specimens has been shown to decrease the number of
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infective viruses in a sample (116). Ten other cell culture-positive patient
specimens were frozen for 2-30 days prior to HSVDISK testing. Despite the

possible decrease in titer, all ten of these specimens were found positive by
HSVDISK.

The HSVDISK method detected one positive result which was not detected
by cell culture or by the Surecell assay. A total of five foci with stained cells were

found in the two HSVDISK wells, indicating that the patient specimen probably
contained a low HSV titer. This patient was experiencing genital blisters at the

time the viral culture was taken. The attending physician suspected the infection
was caused by yeast or HSV, however, no follow up information on the physician’s

final diagnosis of the patient was obtained. Since both wells contained foci with

stained cells, it is not likely that the patient wells were contaminated by carryover
from the positive control, especially since the patient wells were not adjacent to
the positive control well and no other wells on the plate were positive for HSV.

The low titer of HSV present in the specimen may have been inactivated during

transport to the virological lab, or the specimen may have produced such a low

amount of CPE that it was not detected during screening.

Overall, the sensitivity, specificity, positive and negative predictive values

for the HSVDISK system were close to that of cell culture. This result was
expected as the only differences between these two assays are that l)the
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HSVDISK assay uses DNA probe hybridization instead of immunofluorescence

staining to confirm an HSV isolate and that 2)the HSVDISK assay does not
screen for CPE prior to performing a confirmatory test for HSV presence. The

use of an HSV-specific DNA probe gives the HSVDISK assay the ability to detect

HSV in the cell monolayers before the appearance of CPE. Thus all results can be
reported in one day, since it is not necessary to wait for the appearance of HSVcaused CPE before the in situ DNA probe hybridization test is performed.

The Surecell and cell culture tests produced different results for five

specimens. One of these results was the aforementioned abdominal specimen
which yielded a negative result by Surecell and a positive result by standard cell
culture. The other four discrepancies occurred with genital specimens from

symptomatic patients. These specimens were found to be negative by standard
cell culture and the HSVDISK assay but positive by the Surecell assay. Several
reasons could account for the discrepancies. First, these four specimens may have
been false positives in which case the antibody used in the Surecell test to detect
viral antigen may have non-specifically bound to the filter membrane or to some

other substance present in the patient specimen. Non-specific binding of antibody
has been suspected to occur in other immunoassays (88, 94), nevertheless, the
Surecell test formerly demonstrated a high specificity (98.9%) and positive

predictive value (96.7%) in comparison to cell culture (89). Another reason for

the four discrepancies may be that active virus originally present in the patient
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specimen was inactivated during transport, so that active infection of the cell

monolayer was never established in the cell culture and HSVDISK tests. In such
a case, viral antigen in the patient specimen would still have been detected by the

Surecell assay. Loss of infectious HSV may have occurred as a result of improper
collection or mishandling of the specimen prior to receipt in the hospital
laboratory. If this occurred, the 66.6% positive predictive value calculated for the

Surecell test would be falsely low. Loss of infectious HSV during transport most
likely occurred in two of the four patient specimens producing discrepant
HSVDISK and cell culture results, since both of these patients had a history of

genital herpes infection and both were experiencing genital pain, drainage and
lesions at the time the specimens were taken.

The Surecell test is only recommended for use either for confirmation of

cell culture or screening for positives before cell culture is performed. For 37/42
specimens, this assay was able to duplicate cell culture results, making it a rapid,

easy, and accurate screening test for clinics, doctor’s offices and hospitals that
normally send patient specimens to virological labs for cell culturing. The Surecell

assay by itself, however, is not a reliable detector of HSV infection because
patient results are sometimes hard to interpret and because false positive results
may be produced by the assay. On the other hand, HSV present in the patient

specimen need not be viable to be detected by the Surecell assay.
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Though cell culture with confirmation of HSV infection by
immunofluorescence staining, EIA, ELISA, or immunoperoxidase staining is the

most sensitive technique to date, cell culture still takes an average of 3 days before
positive results can be reported to the physician (14, 17), and can take even longer

(up to 14 days) to report an accurate negative result (74). The average time for
isolating HSV in cell culture was 2.2 days and only 30.4% could be detected at 24
hours. The HSVDISK result could be reported in one day and the Surecell result
could be reported in approximately 15 minutes from specimen receipt. For

hospitals such as St. Elizabeth Medical Center which do not have the proper
equipment and/or personnel to perform cell culture, transport time of the
specimen from the hospital lab to the virological lab where cell culturing will be
performed delays reporting of results (usually by one day). Thus rapid and

accurate tests such as the Surecell and HSVDISK assays could be attractive

alternatives to cell culture testing.

One genital culture from an asymptomatic patient was found to be positive

by the HSVDISK and cell culture assays. The patient specimen was found

positive by cell culture at 4 days post-inoculation and only produced two foci of

stained cells per well when tested by the HSVDISK assay. Thus the HSV titer in
the patient specimen was most likely low, as would be expected from a person

who was asymptomatically shedding HSV. Cell culturing and related techniques
have in the past been shown to be poor predictors of asymptomatic genital
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shedding (10). The detection of HSV in the patient specimen was therefore an

unanticipated occurrence. No information on whether the patient had a prior
history of genital HSV infection was available.

No follow-up information was available on the status of the infants of the
pregnant women who tested positive for herpes during pregnancy. Only two of

these women had herpetic lesions at the time the culture was taken. Women will
often times first discover they have a genital HSV-2 infection during pregnancy
(117), because the fluctuations in hormone levels reactivate an HSV-2 infection

contracted prior to pregnancy. Reactivations from the cervix or vagina are
especially a problem when they occur at the time of delivery. If the patient
experiences lesions at this time, it is recommended that the baby be taken by

caesarean section. However, these reactivations of latent HSV do not always

accompany symptoms that are noticeable to the doctor or that would lead the
doctor to perform a caesarean section. During these times of asymptomatic

shedding, the baby may inadvertently be exposed to the virus. Fifty percent of

newborns exposed to HSV at or around the time of delivery will die, and the
majority of those that live will develop sequelae such as mental retardation,

seizures, microcephaly, retinal dysplasia, encephalitis, or meningitis.

Because there are currently no clinically available tests that are sufficiently
rapid and accurate to predict asymptomatic shedding of HSV at the time of

46

delivery, future research in the development of tests sensitive enough to detect
such viral shedding is essential. PCR seems to be the most promising testing

technique for the near future, though widespread use of PCR in clinical labs has
not yet been instituted because of problems associated with purifying patient
specimens (16). Past PCR studies have claimed the detection of asymptomatic

viral shedding in women at delivery (109, 110). These studies have based their
findings on the assumption that viral shedding can only originate from neuronal

cells, and not from non-neuronal cells (such as the cervical or vaginal epithelium).
Other researchers claim that these PCR studies do not distinguish between the

amplification and detection of latent viral DNA and the DNA of viruses that have
been shed from host cells (16). Whether HSV is capable of establishing and
maintaining latency in non-neuronal tissue has long been a matter of debate (118,

119). Most researchers, nevertheless, seem to support that latency can only be
maintained in neuronal cells (1, 2, 109, 110), where latent HSV DNA can be

harbored without being destroyed by immune cells.

Despite the controversy of whether current PCR techniques can detect

asymptomatic viral shedding in pregnant women at delivery, PCR has proven to
be as sensitive and more rapid than cell culture in determining if neonates are

infected with HSV (110), in detecting HSV in the cerebrospinal fluid (CSF) of
persons with HSE (112), and in screening patients for HSV infection (108, 111).
For neonates with HSE, HSV is demonstrable in CSF by cell culture in an
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estimated 25-30% with the infection (56). Brain biopsy has thus far been the most
accurate predictor of HSE infection (56). In a 1991 study performed on seven

neonates with HSV infection, PCR was able to detect HSV DNA in multiple

serum samples of one of the neonates in which cell cultures were repeatedly
negative (110). The high sensitivity and rapidity of the PCR assay for detecting

HSV DNA may in the future make it a preferable technique to cell culturing. In
addition, diagnosis of HSE by performing PCR on serum or CSF samples is a
safer alternative than diagnosis made by brain biopsy.

Development of more sensitive, rapid and accurate HSV diagnostic
techniques would not be necessary if effective vaccines were available. A number

of points must be considered in the development of HSV vaccines (120). First,

the vaccine should provide protection against viral replication in the epithelial cells
of mucous membranes, otherwise the HSV could establish latency in surrounding

neurons. Preventing infection of these epithelial cells by exogenous HSV could be
accomplished by creating a vaccine that will stimulate a strong IgA response in the

recipient.

Secondly, the immunity provided by the vaccine should be long lasting.

Development of attenuated vaccines which can be reactivated from latently

infected cells would be ideal for generating long lasting immunity. The safety of

the vaccine for human usage must also be considered. Since HSVs have been
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implicated in oncogenesis, the use of live or inactivated HSV vaccines is highly
undesirable. If not properly attenuated, these live vaccines could be the basis for

symptomatic infections. Currently, however, vaccine research has been focused on
the development of vaccines based on synthetic viral polypeptides, selective viral

genes cloned into non-HSV vectors, and live genetically engineered HSV, since
these vaccines have no transforming potential. None of the HSV vaccines that
have been tested for therapeutic efficacy in humans have thus far been successful
(121). However, some vaccines tested in animal models have been successful in
providing protection against subsequent HSV exposures (122, 123). The course of

HSV disease in animals and susceptibility of the animals to HSV infection differs
in comparison to humans. Therefore success of vaccines in animal models does

not necessarily indicate that these vaccines will be efficacious for human usage.
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CONCLUSION

Presently there is no single diagnostic assay that is rapid or sensitive

enough to detect HSV in pregnant women near delivery, in immunocompromised

patients, or in persons with suspected HSE. PCR appears to be the most
promising rapid diagnostic technique for the future. Further refinements with this

method could produce an HSV diagnostic test that is less cumbersome and more
rapid than cell culture. Based on data acquired in this research, assays such as the
Surecell and HSVDISK assays can, however, provide dependable alternatives to

standard cell culture. The HSVDISK assay is a cell culture method that is

compact, easy to work with and requires minimal prior experience with cell
culture. The in situ DNA probe eliminates the need of daily cell culture screening
for CPE and since cells are delivered weekly, there is no need for the
maintenance of a cell culture line. In addition, results are easy to read and can be
obtained in 24 hours. The HSVDISK assay, however, can only be used in a lab
that has access to or is equipped with a laminar flow hood, centrifuge, humidified

incubator, -70°C freezer (for freezing controls) and an inverted light microscope.
Overall the HSVDISK assay produced results comparable to standard cell culture,
making it a dependable alternative to the cell culture method.

The Surecell test is particularly appealing for hospitals, clinics, and doctor’s
offices that cannot afford to maintain expensive cell culturing equipment and

SO

experienced staff. Since the test can be performed in less than 15 minutes, it is an

excellent screening test for HSV, either directly from the swab or from swabs
-placed in viral-transport-medium. One of the drawbacks with the Surecell assay is
that the interpretation of the result is not always clear, especially if the specimen
swab contains a low titer of HSV. Because the positives are not always evident, at

least one swab (or excess viral transport medium) should be reserved for cell

culturing if a negative result is obtained by the Surecell assay. Despite this
drawback, the Surecell assay is easy to perform and requires no specialized

equipment. The Surecell assay could also be used as a confirmatory technique for

viral isolates from cell culture, since the assay only takes a few minutes to
perform.

In conclusion the continual evaluation of HSV diagnostic tests provides a

service to hospitals, clinics, and doctor’s offices that do not have the funding or
the means to randomly try out various tests to see which is the most appropriate

for their purposes. Moreover this research as well as other HSV research
concerning cures, therapy, and prevention helps to a)provide more efficient

patient care b)limit the prevalance of HSV infections and the significant morbidity
and mortality associated with HSV infections and c)ease the psychosocial impact

on persons with genital herpes.
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TABLE 1

Comparison of HSV detection by HSVDISK in situ DNA probe assay to HSV
isolation by standard cell culture

Standard Cell Culture
HSVDISK
result

No.

No. positive

No. negative

Positive

21

20

1

Negative

131

2

129

52

TABLE 2

Comparison of HSV detection by Surecell enzyme immunoassay to HSV
isolation by standard cell culture

Standard Cell Culture
Surecell
result

No.

No. positive

No. negative

Positive

12

8

4

Negative

30

1

29

S3

TABLE 3

Performance assessment of Surecell and HSVDISK test in comparison to
standard cell culture3

Test

HSVDISK”

SurecelP

Sensitivity

Specificity

20/22
(90.9%)d

129/130
(99.2%)

8/9
(88.9%)

23/33
(87.9%)

Predictive Value
Positive
Negative

20/21
(95.2%)

129/131
(98.5%)

8/12
(66.6%)

29/30
(96.7%)

3 Sensitivity, specificity, and positive and negative predictive values were calculated

according to equations found in the Materials and Methods
b Total specimens analyzed: 152
c Total specimens analyzed: 42

d Percentages were in relation to cell culture which was considered to be 100%
accurate in the determination of whether a patient specimen was positive or

negative
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TABLE 4

Detection of HSV by cell culture at various times post-inoculation

Cell Culture Incubation3

No. HSV Positive (%)b

1

7 (30.4%)

2

8 (65.2%)

3

4 (82.6%)

4

4 (100.0%)

a Times listed do not take into account transport time from the hospital laboratory

to the virological laboratory where cell culture testing was performed
b A total of 23 patient specimens were positive by cell culture
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